Cervomed announces key takeaways from oral presentations at the 17th clinical trials on alzheimer's disease conference (ctad)

Data from the ascend-lb phase 2a trial in dlb confirm recent scientific literature indicating that plasma glial fibrillary acid protein (gfap) is a robust measure of neurodegenerative disease activity in dlb
CRVO Ratings Summary
CRVO Quant Ranking